ProShare Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-20,973
| Closed | -$806K | – | 1892 |
|
|
2023
Q2 | $806K | Buy |
20,973
+10,441
| +99% | +$268K | ﹤0.01% | 774 |
|
|
2023
Q1 | $244K | Sell |
10,532
-1,279
| -11% | -$30.5K | ﹤0.01% | 1327 |
|
|
2022
Q4 | $309K | Buy |
11,811
+1,023
| +9% | +$22.7K | ﹤0.01% | 1225 |
|
|
2022
Q3 | $211K | Buy |
+10,788
| New | +$216K | ﹤0.01% | 1375 |
|
|
2022
Q2 | – | Sell |
-13,041
| Closed | -$214K | – | 2225 |
|
|
2022
Q1 | $214K | Sell |
13,041
-2,940
| -18% | -$40K | ﹤0.01% | 1849 |
|
|
2021
Q4 | $260K | Buy |
15,981
+2,169
| +16% | +$30.9K | ﹤0.01% | 1874 |
|
|
2021
Q3 | $176K | Sell |
13,812
-2,363
| -15% | -$31.1K | ﹤0.01% | 1818 |
|
|
2021
Q2 | $228K | Buy |
+16,175
| New | +$259K | ﹤0.01% | 2068 |
|
|
2019
Q4 | – | Sell |
-5,831
| Closed | -$31K | – | 1810 |
|
|
2019
Q3 | $31K | Sell |
5,831
-201
| -3% | -$1.33K | ﹤0.01% | 1630 |
|
|
2019
Q2 | $46K | Sell |
6,032
-779
| -11% | -$11.9K | ﹤0.01% | 1578 |
|
|
2019
Q1 | $136K | Buy |
6,811
+76
| +1% | +$1.32K | ﹤0.01% | 1536 |
|
|
2018
Q4 | $89K | Sell |
6,735
-1,283
| -16% | -$25.6K | ﹤0.01% | 1485 |
|
|
2018
Q3 | $295K | Sell |
8,018
-289
| -3% | -$9.28K | ﹤0.01% | 1368 |
|
|
2018
Q2 | $291K | Buy |
8,307
+8
| +0.1% | +$307 | ﹤0.01% | 1402 |
|
|
2018
Q1 | $386K | Sell |
8,299
-1,367
| -14% | -$50K | ﹤0.01% | 1207 |
|
|
2017
Q4 | $362K | Buy |
9,666
+664
| +7% | +$29K | ﹤0.01% | 1287 |
|
|
2017
Q3 | $479K | Buy |
9,002
+1,105
| +14% | +$65.7K | ﹤0.01% | 978 |
|
|
2017
Q2 | $450K | Sell |
7,897
-91
| -1% | -$4.57K | ﹤0.01% | 994 |
|
|
2017
Q1 | $429K | Sell |
7,988
-2,028
| -20% | -$115K | ﹤0.01% | 1067 |
|
|
2016
Q4 | $571K | Buy |
10,016
+1,148
| +13% | +$69.4K | 0.01% | 1016 |
|
|
2016
Q3 | $551K | Sell |
8,868
-1,619
| -15% | -$114K | 0.01% | 917 |
|
|
2016
Q2 | $593K | Buy |
10,487
+923
| +10% | +$56.1K | 0.01% | 894 |
|
|
2016
Q1 | $613K | Sell |
9,564
-695
| -7% | -$56.2K | 0.01% | 908 |
|
|
2015
Q4 | $1.44M | Buy |
+10,259
| New | +$1.39M | 0.02% | 612 |
|
ProShare Advisors's KDNY Position: Q3 2023 in Review
ProShare Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 20,973 shares — an estimated $806K sold.
ProShare Advisors first reported a position in KDNY in Q4 2015 and held it in 24 quarters. The position peaked at $1.44M in Q4 2015. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- ProShare Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- ProShare Advisors sold 20,973 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $806K.
- ProShare Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 24 quarters.
- ProShare Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $1.44M in Q4 2015.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on ProShare Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.